Further, we verified the value of CD44 as a predictor for ICB efficacy, as a result, CD44 down-regulation was related to better immunotherapy response in a melanoma cohort undergoing anti-PD-1 therapy (GSE91061), and CD44 expression of non-response group markedly elevated (Figure 8D). Here, CD44 is linked to melanoma.